Auspex adds weight as it raises $25m to progress deuterium-modified pipeline
This article was originally published in Scrip
Executive Summary
Auspex Pharmaceuticals has raised $25 million in a Series D venture financing round to conduct a pivotal Phase III clinical trial for SD-809, a version of the drug Xenazine (tetrabenazine) for the treatment of chorea associated with Huntington's disease, in which the San Diego-based company believes it has improved pharmacokinetic properties by substituting certain hydrogen atoms with the "heavy" hydrogen isotope deuterium.
You may also be interested in...
Sanofi Clinches Key Phase III Immunology Win With Rilzabrutinib
Sanofi’s BTK inhibitor – one of two from its 2021 Principia buy – passed a Phase III test in immune thrombocytopenia as the company focuses on Dupixent-like blockbusters going forward.
Ipsen Expands Its Rare Neurological Disease Pipeline With Skyhawk Deal
Deal Snapshot: Ipsen committed up to $1.8bn in upfront and milestone fees to develop novel treatments for rare neurological diseases with Skyhawk’s RNA-targeting small molecule platform.
Finance Watch: Canaan, Regeneron Reveal New Funds For Start-Ups
Private Company Edition: Regeneron launched a $500m venture fund and Canaan added $100m, bringing the venture firm’s recent total to $1bn-plus. Also, incubators plan to grow over the next decade and in recent financings Avenzo raised $150m and Nvelop launched with $100m.